

REMARKS/ARGUMENTS

Claims 1-18 and 45-62 are active in this application. Claims 1-10 and 45-54 are drawn to the elected subject matter. With respect to Claims 11-18 and 55-62, Applicants request that these claims, which have been amended to depend from the elected claims, be included within the elected group of claims when this application is allowed. Support for Claims 45-62 is found in Claims 1-18 and the specification on 4-5, and 16-17.

The specification is amended to update the information concerning the copending applications on page 16 and to correct clerical errors. In particular, the enzyme involved in Fabry's disease is α -galactosidase not β -galactosidase (see attached printout from a Fabry's disease internet information site), the enzyme involved in Morquio Syndrome is β -galactosidase (see the attached printout from the Medline plus, online medical dictionary), and the enzyme involved in Mucopolidosis is Ganglioside sialidase (see the attached printout from The GAPS Index to information on the Internet about Genetic Disorders and Birth Defects). Corresponding changes have been made in the appropriate claims as well. The specification has also been amended to correct the typographical error changing *Pseudomonas* exodotoxin A to *Pseudomonas* exotoxin A (see the attached copy of Moehring and Moehring (1983) *Infection and Immunity* 41(3):998-1009, cited on pages 14 and 15). No new matter is added by the amendments. Favorable reconsideration is requested.

The rejection of Claims 1-6 under 35 U.S.C. § 112, second paragraph have been addressed by amendment. Therefore, withdrawal of this ground of rejection is requested.

The rejection of Claim 2 under 35 U.S.C. § 112, first paragraph is addressed by amendment.

As noted above, the enzyme involved in Fabry's disease is α -galactosidase not β -galactosidase (see attached printout from a Fabry's disease internet information site), and the enzyme involved in Morquio Syndrome is β -galactosidase (see the attached printout from the

Medline plus, online medical dictionary). The specification has been amended to correct the clerical error. Therefore, withdrawal of this ground of rejection is requested.

The rejection of Claims 1-10 under 35 U.S.C. § 112, first paragraph is respectfully traversed.

The specification has also been amended to correct the typographical error changing *Pseudomonas* exodotoxin A to *Pseudomonas* exotoxin A (see the attached copy of Moehring and Moehring (1983) *Infection and Immunity* 41(3):998-1009, cited on pages 14 and 15). Therefore, the specification supports the claims as filed. Withdrawal of this ground of rejection is requested.

Information Disclosure Statements

Since the references filed as part of the Information Disclosure Statement could not be located, Applicants are filing additional copies of those patents for the Examiner's consideration. A new PTO Form 1449 is also attached listing those references. A return, signed copy of the PTO-1449 is requested. In addition, attached is a International Search Report and the references cited in a related PCT application. Two of the cited publications, Zhao and Lee have already been submitted and considered. The third publication of Do et al., was published August 2002.


Application No. 10/023,894

Reply to Office Action of October 21, 2003

Finally, Applicants request that the application be passed to issuance.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

A handwritten signature in black ink, appearing to read 'R. Chinn', is written over a horizontal line.

Richard L. Chinn, Ph.D.
Attorney of Record
Registration No. 34,305

Daniel J. Pereira, Ph.D.
Registration No. 45,518

Customer Number

22850

Tel: (703) 413-3000

Fax: (703) 413 -2220